Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia
Clinical trial NCT03663829 · COMPLETED
Trial details
- NCT number
- NCT03663829
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2017-10-04
- Primary completion
- 2019-03-05
- Enrollment
- 2052
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.